5 Key Takeaways
-
1
Gene therapy represents a significant advancement in treating inherited retinal diseases (IRDs), with one FDA-approved option currently available.
-
2
Eligibility for gene therapy is primarily determined by genetic testing, requiring specific pathogenic variants to be identified.
-
3
Patients may have unrealistic expectations about gene therapy outcomes, often believing it can restore vision to normal.
-
4
Involving genetic counselors can aid in interpreting test results and clarifying eligibility for gene therapy.
-
5
Providers should discuss expected outcomes with patients to align treatment options with their personal goals and values.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







